Cargando…
IFNγ score–based neoadjuvant immunotherapy for stage III melanoma
In this issue of JEM, Reijers et al. (2023. J. Exp. Med. https://doi.org/10.1084/jem.20221952) demonstrate that pre- and post-treatment IFNγ-related gene expression scores are promising markers for choosing neoadjuvant immunotherapy for stage III melanoma.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Rockefeller University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035434/ https://www.ncbi.nlm.nih.gov/pubmed/36920330 http://dx.doi.org/10.1084/jem.20230160 |